Announcement PDF RNS Number : 5017Q Shield Therapeutics PLC 26 February 2021 Shield Therapeutics plc ("Shield" or the "Group") Total Voting Rights Update London, UK, 26 February 2021: Shield Therapeutics plc (LSE: STX), a commercial stage, pharmaceutical company with a focus on addressing iron deficiency with its lead product Feraccru®/Accrufer® (ferric maltol), confirms that in accordance with the requirements of the FCA's Disclosure and Transparency Rule 5.6.1, the Company's issued share capital consists of 118,544,379 ordinary shares of 1.5p each in issue, each with equal voting rights. No shares are held in treasury. The above figure may also be used by shareholders as the denominator in the calculations by which they will determine whether they are required to notify their interest, or a change to their interest, in the Company under the FCA's Disclosure Guidance and Transparency Rules. For further information please contact: Shield Therapeutics plc Tim Watts, Chief Executive Officer Lucy Huntington-Bailey, General Counsel and Company Secretary Nominated Advisor and Broker Peel Hunt LLP James Steel/Dr Christopher Golden Joint Broker finnCap Ltd Geoff Nash/Matt Radley/Alice Lane Financial PR & IR Advisor Walbrook PR Paul McManus/Lianne Cawthorne www.shieldtherapeutics.com +44 (0)19 1511 8500 +44 (0) 19 1511 8500 +44 (0)20 7418 8900 +44 (0)20 7220 0500 +44 (0)20 7933 8780 or shield@walbrookpr.com +44 (0)7980 541 893 / +44 (0)7584 391 303 About Shield Therapeutics plc Shield is a commercial stage, pharmaceutical company with a focus on addressing iron deficiency with its lead product Feraccru ® /Accrufer ® (ferric maltol) ®, a novel, stable, non-salt based oral therapy for adults with iron deficiency with or without anaemia. Shield is quoted on AIM (STX). For more information about Shield, please see www.shieldtherapeutics.com This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com. RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy. END TVRBQLFLFLLFBBX